Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.59 |
| ▸ | PARP2 | Q9UGN5 | 9/20 | 0.59 |
| ▸ | PARP3 | Q9Y6F1 | 9/20 | 0.59 |
| ▸ | TNKS | O95271 | 1/20 | 0.58 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.58 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4323093 | 0.90 | KDM4E (0.58) | PARP1PARP2PARP3TNKSPARP6 | |
| SCHEMBL4319210 | 0.89 | KDM4E (0.54) | PARP1PARP2PARP3TNKSPARP6 | |
| SCHEMBL4422043 | 0.87 | KDM4E (0.52) | PARP1PARP2PARP3KDM4EALDH1A1 | |
| SCHEMBL4417052 | 0.82 | HSD11B1 (0.76) | — | |
| SCHEMBL26295625 | 0.82 | ALDH1A1 (0.69) | PARP1PARP2PARP3TNKSPARP6 | |
| SCHEMBL12203374 | 0.81 | PARP1 (0.63) | PARP1PARP2PARP3TNKSPARP6 | |
| SCHEMBL4321986 | 0.80 | MEN1 (0.69) | KDM4EALDH1A1 | |
| SCHEMBL5901321 | 0.78 | KDM4E (0.68) | KDM4EALDH1A1TDP1 | |
| SCHEMBL94920 | 0.78 | KDM4E (0.64) | PARP1PARP2PARP3TNKSPARP6 | |
| SCHEMBL4413754 | 0.78 | MEN1 (0.52) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | PARP1 4588/4885PARP2 4621/4885PARP3 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.